-
Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorder
Wednesday, April 21, 2021 - 9:25am | 258Read More...Alterity Therapeutics (NASDAQ: ATHE) has announced the presentation of expanded animal data to support the commercialization of its lead compound ATH434 in development to treat Parkinsonian disorders. Data were presented at the American Academy of Neurology virtual annual...
-
Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive Impairment
Tuesday, April 6, 2021 - 6:57am | 214Read More...Aptinyx Inc (NASDAQ: APTX) has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and dementia with Lewy bodies. Aptinyx will release the data from this...
-
Adamas' Gocovri Treatment Doubles ON Time Without Dyskinesia In Parkinson's disease, New Analysis Shows
Monday, March 29, 2021 - 3:12pm | 293Read More...Adamas Pharmaceuticals Inc (NASDAQ: ADMS) has announced the publication of pooled analyses of Gocovri (amantadine) from pivotal studies in Parkinson's disease. Data were published in the peer-reviewed journal Frontiers in Neurology. The publication examined data from two...
-
Annovis Bio Stock Is Trading Higher After Parkinson's Med Shows Improvement In Speed, Coordination
Tuesday, March 16, 2021 - 9:24am | 327Read More...Annovis Bio Inc (NYSE: ANVS) reported positive interim data from Phase 2a trial evaluating ANVS401, its lead drug candidate for Alzheimer's disease (AD) and Parkinson's disease (PD). In one test that measures the speed of execution, the results were statistically...
-
AbbVie To Beef Up Neurology Pipeline With Option To Add Parkinson's Candidate
Tuesday, March 2, 2021 - 12:18pm | 194Read More...AbbVie Inc (NYSE: ABBV) has landed an option to buy Mitokinin upon completing IND-enabling studies on the latter's lead PINK1 compound for Parkinson's disease. Mitokinin's novel PINK1 compounds selectively increase the activity of PINK1, a master regulator of...
-
Inhibikase Initiates Early-Stage Study Of Parkinson's Candidate
Wednesday, February 17, 2021 - 1:48pm | 230Read More...Inhibikase Therapeutics Inc (NASDAQ: IKT) has dosed the first patients in its Phase 1 trial of IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, for the treatment of Parkinson's disease. This randomized Phase 1 study in healthy volunteers will assess the safety,...
-
Yumanity Therapeutics Sees Lead Candidate Interim Data From Early-Stage Parkinson's Study By Mid-2021
Wednesday, February 10, 2021 - 1:02pm | 274Read More...Yumanity Therapeutics Inc (NASDAQ: YMTX) reported results from the Phase 1 single ascending dose study in 40-healthy volunteers, evaluating its lead candidate, YTX-7739, an SCD inhibitor, for the treatment of Parkinson's disease. No safety concerns were identified, and YTX-7739...
-
Oppenheimer: Axovant Deal Transform Pipeline
Thursday, June 7, 2018 - 1:33pm | 357Read More...Axovant Sciences Ltd (NASDAQ: AXON) announced Wednesday that it licensed global rights to Oxford BioMedica’s investigational gene therapy for Parkinson’s Disease. As some experts see it, the drug could be a game changer. The Rating Oppenheimer analysts Jay Olson and Silvan Tuerkcan...
-
Acorda Therapeutics To Acquire Biotie Therapies To Boost Its Parkinson's Disease Therapeutic Development
Tuesday, January 19, 2016 - 10:40am | 322Read More...Acorda Therapeutics Inc (NASDAQ: ACOR), a biopharmaceutical company that develops therapies for neurological disorders, on Tuesday announced that it has acquired Biotie Therapies Oyj (ADR) (NASDAQ: BITI) for $25.60 per ADS. Biotie Therapies is a Finland-based drug development company...
-
Minerva Neurosciences Soars 60% Following Parkinson's Disease Treatment News
Tuesday, January 6, 2015 - 10:21am | 202Read More...Shares of Minerva Neurosciences Inc (NASDAQ: NERV) soared over 60 percent in Tuesday’s premarket following positive news on its Parkinson’s Disease treatment. The company announced that results from a Primomed (use of PRIMate MOdels to support translational MEDicine) non-human...
